This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 11, 2013 /PRNewswire/ --
Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA for the same.
Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s Aciphex® delayed-release tablets, 20mg, and are indicated for the treatment of Gastroesophageal reflux disease (GERD). Aciphex® delayed-release tablets, 20mg, had annual U.S sales of approximately
US$ 864.3 million (IMS MAT
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in
South Africa (IMS).
For the financial year ended
March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (
USD 1.74 billion) and Rs. 13,142 million (
USD 242 million) respectively. Please visit
http://www.lupinworld.com for more information.
Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit
For more information, please contact -